APA

Othman A. A., Khatri A., Loebbert R. & Peloso P. M. (20200728). Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. : Clinical pharmacology in drug development.

Chicago

Othman Ahmed A, Khatri Amit, Loebbert Ralf and Peloso Paul M. 20200728. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. : Clinical pharmacology in drug development.

Harvard

Othman A. A., Khatri A., Loebbert R. and Peloso P. M. (20200728). Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. : Clinical pharmacology in drug development.

MLA

Othman Ahmed A, Khatri Amit, Loebbert Ralf and Peloso Paul M. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. : Clinical pharmacology in drug development. 20200728.